KIR3DL1 and neoplasm: In a separate Eastern Cooperative Oncology Group (ECOG) Phase III clinical trial of low-tumor burden FL (2), patients who were KIR3DL1+/HLA-Bw4+ and treated with a continuous regimen of maintenance rituximab had improved duration of response and % tumor shrinkage compared to KIR3DL1+/HLA-Bw4+ patients who were randomized to not receive maintenance rituximab (22, 23).